BlackRock, Inc. 13D and 13G filings for Lineage Cell Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-05 5:28 pm Purchase | 2024-12-31 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 10,094,677 4.600% | 174,877 (+1.76%) | Filing |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 9,919,800 5.300% | 0 (Unchanged) | Filing |
| 2024-10-22 3:24 pm Purchase | 2024-09-30 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 9,919,800 5.300% | 6,164,043 (+164.12%) | Filing |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 3,755,757 2.200% | -6,252,753 (-62.47%) | Filing |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 10,008,510 5.900% | 10,008,510 (New Position) | Filing |